Abivax said 50% of patients achieved endoscopic remission at the end of maintenance and plans to file by the end of the year, with one batch submitted 30 days later without changing the review timetable.
ABVX · Abivax S.A.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Sep 21, 2026
- Price history
- Oct 2023 to Nov 2026
Up next
Latest documents
Abivax SA reported a €165.9 million net loss for the six months ended June 30, 2026, completed a July 2026 ADS offering generating approximately $874.1 million in net proceeds, and said liquidity would fund operations for at least 12 months.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABVX
this stock
Abivax S.A.
|
$7.06B | -40.2% | — | — | 4.7% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 13
Abivax said 50% of patients achieved endoscopic remission at the end of maintenance and plans to file by the end of the year, with one batch submitted 30 days later without changing the review timetable.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABVX | -10.6% | -10.6% | -37.8% | -6.9% | -40.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -5.1% | -4.3% | -32.2% | -1.6% | -45.2% |